The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing–remitting multiple sclerosis
Objective Two pilot studies were conducted to evaluate safety, tolerability, and efficacy of two doses of Protiramer (TV-5010) in patients with relapsing–remitting multiple sclerosis. Background Both glatiramer acetate and TV-5010 are synthetic copolymers comprised the same four amino acids in a def...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2009-02, Vol.15 (2), p.238-243 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 243 |
|---|---|
| container_issue | 2 |
| container_start_page | 238 |
| container_title | Multiple sclerosis |
| container_volume | 15 |
| creator | De Stefano, N Filippi, M Confavreux, C Vermersch, P Simu, M Sindic, C Hupperts, R Bajenaru, O Edan, G Grimaldi, L Marginean, I Medaer, R Orefice, G Pascu, I Pelletier, J Sanders, E Scarpini, E Mancardi, GL |
| description | Objective
Two pilot studies were conducted to evaluate safety, tolerability, and efficacy of two doses of Protiramer (TV-5010) in patients with relapsing–remitting multiple sclerosis.
Background
Both glatiramer acetate and TV-5010 are synthetic copolymers comprised the same four amino acids in a defined molar ratio. TV-5010 has higher average molecular weight than Glatiramer acetate and might be hypothesized that glatiramoids with higher molecular weight might be more immunoreactive than lower molecular weight peptides, thus increasing therapeutic potential and allowing for less frequent dosing.
Methods
In the two separate studies, after a 10 week pretreatment period, TV-5010 was given subcutaneously once weekly at 15 mg and 30 mg for 36 weeks. The primary end point was a reduction in the number of magnetic resonance imaging active lesions (i.e., T1-weigthed gadolinium-enhancing and new T2-weighted lesions) between the pretreatment period and the end of study.
Results
Both TV-5010 doses were generally well tolerated. The treatment with TV-5010 at a dose of 15 mg/wk did not show any significant effect. In contrast, in patients treated with at a dose of 30 mg/wk, a significant reduction in the mean number of gadolinium-enhancing (−58.8%; P = 0.0013) and new T2-W (−50%; P = 0.0002) lesions was observed. However, a large decrease in the mean number of both gadolinium-enhancing (−55%) and new T2-W (−40%) lesions during the pretreatment period made difficult the interpretation of the efficacy assessments.
Conclusions
Further studies are needed to confirm these preliminary data on safety and efficacy of TV-5010 at a weekly dose of 30 mg. |
| doi_str_mv | 10.1177/1352458508098269 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66874634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458508098269</sage_id><sourcerecordid>20449440</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-be3fb9d81a7f9ea679c5e975e5f96b47e9d83f6827ca7bee321d37d9e22bbf843</originalsourceid><addsrcrecordid>eNqFkk2LFDEQhhtR3HX17kmCoKdpTbqTTnKUxS9Y8LKem3S6MpMl_WEqzezc_A_-Pw_-EtPO4MKCeKoq6qm33oIqiueMvmFMyresFhUXSlBFtaoa_aA4Z1zKkmpJH-Y8t8u1f1Y8QbyhlEpZi8fFGVNaSUbr8-Ln9Q5IBFxCQjI5kvYTGXLhLYwJ4oZMM4xlMB0EgmnpPSAxiIDoxy0B57w19rAhaQoQTeeDTwdixp6gcZDTLDnHKflohlXNkJ3f7siQabsEE8kecp0IHsa0g7yV2GmewiHDOR_8bVoibIgfyWySz5aQ7H3aZcfBzKuFX99_RBh8SqudP8bnAARtdjOhx6fFI2cCwrNTvCi-fnh_ffmpvPry8fPlu6vS8kaksoPadbpXzEinwTRSWwFaChBONx2XkHu1a1QlrZEdQF2xvpa9hqrqOqd4fVG8PurmY78tgKkdPFoIwYwwLdg2jZK8qf8PVpRzzTnN4Mt74M20xDEf0VZMKSqEqjJEj5DN12IE187RDyYeWkbb9UPa-x-SR16cdJdugP5u4PQSGXh1AgxaE1w0o_X4l6sY45QLkbnyyKHZwp25fy7-DXRs2EY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218805582</pqid></control><display><type>article</type><title>The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing–remitting multiple sclerosis</title><source>MEDLINE</source><source>SAGE Complete</source><creator>De Stefano, N ; Filippi, M ; Confavreux, C ; Vermersch, P ; Simu, M ; Sindic, C ; Hupperts, R ; Bajenaru, O ; Edan, G ; Grimaldi, L ; Marginean, I ; Medaer, R ; Orefice, G ; Pascu, I ; Pelletier, J ; Sanders, E ; Scarpini, E ; Mancardi, GL</creator><creatorcontrib>De Stefano, N ; Filippi, M ; Confavreux, C ; Vermersch, P ; Simu, M ; Sindic, C ; Hupperts, R ; Bajenaru, O ; Edan, G ; Grimaldi, L ; Marginean, I ; Medaer, R ; Orefice, G ; Pascu, I ; Pelletier, J ; Sanders, E ; Scarpini, E ; Mancardi, GL</creatorcontrib><description>Objective
Two pilot studies were conducted to evaluate safety, tolerability, and efficacy of two doses of Protiramer (TV-5010) in patients with relapsing–remitting multiple sclerosis.
Background
Both glatiramer acetate and TV-5010 are synthetic copolymers comprised the same four amino acids in a defined molar ratio. TV-5010 has higher average molecular weight than Glatiramer acetate and might be hypothesized that glatiramoids with higher molecular weight might be more immunoreactive than lower molecular weight peptides, thus increasing therapeutic potential and allowing for less frequent dosing.
Methods
In the two separate studies, after a 10 week pretreatment period, TV-5010 was given subcutaneously once weekly at 15 mg and 30 mg for 36 weeks. The primary end point was a reduction in the number of magnetic resonance imaging active lesions (i.e., T1-weigthed gadolinium-enhancing and new T2-weighted lesions) between the pretreatment period and the end of study.
Results
Both TV-5010 doses were generally well tolerated. The treatment with TV-5010 at a dose of 15 mg/wk did not show any significant effect. In contrast, in patients treated with at a dose of 30 mg/wk, a significant reduction in the mean number of gadolinium-enhancing (−58.8%; P = 0.0013) and new T2-W (−50%; P = 0.0002) lesions was observed. However, a large decrease in the mean number of both gadolinium-enhancing (−55%) and new T2-W (−40%) lesions during the pretreatment period made difficult the interpretation of the efficacy assessments.
Conclusions
Further studies are needed to confirm these preliminary data on safety and efficacy of TV-5010 at a weekly dose of 30 mg.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458508098269</identifier><identifier>PMID: 18987103</identifier><identifier>CODEN: MUSCFZ</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Biological and medical sciences ; Chemistry, Pharmaceutical ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Dose-Response Relationship, Drug ; Female ; Glatiramer Acetate ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - chemistry ; Injections, Subcutaneous ; Male ; Medical sciences ; Molecular Weight ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Neurology ; Peptides - administration & dosage ; Peptides - adverse effects ; Peptides - chemistry ; Pilot Projects ; Treatment Outcome</subject><ispartof>Multiple sclerosis, 2009-02, Vol.15 (2), p.238-243</ispartof><rights>2009 INIST-CNRS</rights><rights>SAGE Publications © Feb 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-be3fb9d81a7f9ea679c5e975e5f96b47e9d83f6827ca7bee321d37d9e22bbf843</citedby><cites>FETCH-LOGICAL-c465t-be3fb9d81a7f9ea679c5e975e5f96b47e9d83f6827ca7bee321d37d9e22bbf843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458508098269$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458508098269$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21140455$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18987103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Stefano, N</creatorcontrib><creatorcontrib>Filippi, M</creatorcontrib><creatorcontrib>Confavreux, C</creatorcontrib><creatorcontrib>Vermersch, P</creatorcontrib><creatorcontrib>Simu, M</creatorcontrib><creatorcontrib>Sindic, C</creatorcontrib><creatorcontrib>Hupperts, R</creatorcontrib><creatorcontrib>Bajenaru, O</creatorcontrib><creatorcontrib>Edan, G</creatorcontrib><creatorcontrib>Grimaldi, L</creatorcontrib><creatorcontrib>Marginean, I</creatorcontrib><creatorcontrib>Medaer, R</creatorcontrib><creatorcontrib>Orefice, G</creatorcontrib><creatorcontrib>Pascu, I</creatorcontrib><creatorcontrib>Pelletier, J</creatorcontrib><creatorcontrib>Sanders, E</creatorcontrib><creatorcontrib>Scarpini, E</creatorcontrib><creatorcontrib>Mancardi, GL</creatorcontrib><title>The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing–remitting multiple sclerosis</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Objective
Two pilot studies were conducted to evaluate safety, tolerability, and efficacy of two doses of Protiramer (TV-5010) in patients with relapsing–remitting multiple sclerosis.
Background
Both glatiramer acetate and TV-5010 are synthetic copolymers comprised the same four amino acids in a defined molar ratio. TV-5010 has higher average molecular weight than Glatiramer acetate and might be hypothesized that glatiramoids with higher molecular weight might be more immunoreactive than lower molecular weight peptides, thus increasing therapeutic potential and allowing for less frequent dosing.
Methods
In the two separate studies, after a 10 week pretreatment period, TV-5010 was given subcutaneously once weekly at 15 mg and 30 mg for 36 weeks. The primary end point was a reduction in the number of magnetic resonance imaging active lesions (i.e., T1-weigthed gadolinium-enhancing and new T2-weighted lesions) between the pretreatment period and the end of study.
Results
Both TV-5010 doses were generally well tolerated. The treatment with TV-5010 at a dose of 15 mg/wk did not show any significant effect. In contrast, in patients treated with at a dose of 30 mg/wk, a significant reduction in the mean number of gadolinium-enhancing (−58.8%; P = 0.0013) and new T2-W (−50%; P = 0.0002) lesions was observed. However, a large decrease in the mean number of both gadolinium-enhancing (−55%) and new T2-W (−40%) lesions during the pretreatment period made difficult the interpretation of the efficacy assessments.
Conclusions
Further studies are needed to confirm these preliminary data on safety and efficacy of TV-5010 at a weekly dose of 30 mg.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Chemistry, Pharmaceutical</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Glatiramer Acetate</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - chemistry</subject><subject>Injections, Subcutaneous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Molecular Weight</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Neurology</subject><subject>Peptides - administration & dosage</subject><subject>Peptides - adverse effects</subject><subject>Peptides - chemistry</subject><subject>Pilot Projects</subject><subject>Treatment Outcome</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkk2LFDEQhhtR3HX17kmCoKdpTbqTTnKUxS9Y8LKem3S6MpMl_WEqzezc_A_-Pw_-EtPO4MKCeKoq6qm33oIqiueMvmFMyresFhUXSlBFtaoa_aA4Z1zKkmpJH-Y8t8u1f1Y8QbyhlEpZi8fFGVNaSUbr8-Ln9Q5IBFxCQjI5kvYTGXLhLYwJ4oZMM4xlMB0EgmnpPSAxiIDoxy0B57w19rAhaQoQTeeDTwdixp6gcZDTLDnHKflohlXNkJ3f7siQabsEE8kecp0IHsa0g7yV2GmewiHDOR_8bVoibIgfyWySz5aQ7H3aZcfBzKuFX99_RBh8SqudP8bnAARtdjOhx6fFI2cCwrNTvCi-fnh_ffmpvPry8fPlu6vS8kaksoPadbpXzEinwTRSWwFaChBONx2XkHu1a1QlrZEdQF2xvpa9hqrqOqd4fVG8PurmY78tgKkdPFoIwYwwLdg2jZK8qf8PVpRzzTnN4Mt74M20xDEf0VZMKSqEqjJEj5DN12IE187RDyYeWkbb9UPa-x-SR16cdJdugP5u4PQSGXh1AgxaE1w0o_X4l6sY45QLkbnyyKHZwp25fy7-DXRs2EY</recordid><startdate>20090201</startdate><enddate>20090201</enddate><creator>De Stefano, N</creator><creator>Filippi, M</creator><creator>Confavreux, C</creator><creator>Vermersch, P</creator><creator>Simu, M</creator><creator>Sindic, C</creator><creator>Hupperts, R</creator><creator>Bajenaru, O</creator><creator>Edan, G</creator><creator>Grimaldi, L</creator><creator>Marginean, I</creator><creator>Medaer, R</creator><creator>Orefice, G</creator><creator>Pascu, I</creator><creator>Pelletier, J</creator><creator>Sanders, E</creator><creator>Scarpini, E</creator><creator>Mancardi, GL</creator><general>SAGE Publications</general><general>Sage Publications</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20090201</creationdate><title>The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing–remitting multiple sclerosis</title><author>De Stefano, N ; Filippi, M ; Confavreux, C ; Vermersch, P ; Simu, M ; Sindic, C ; Hupperts, R ; Bajenaru, O ; Edan, G ; Grimaldi, L ; Marginean, I ; Medaer, R ; Orefice, G ; Pascu, I ; Pelletier, J ; Sanders, E ; Scarpini, E ; Mancardi, GL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-be3fb9d81a7f9ea679c5e975e5f96b47e9d83f6827ca7bee321d37d9e22bbf843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Chemistry, Pharmaceutical</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Glatiramer Acetate</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - chemistry</topic><topic>Injections, Subcutaneous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Molecular Weight</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Neurology</topic><topic>Peptides - administration & dosage</topic><topic>Peptides - adverse effects</topic><topic>Peptides - chemistry</topic><topic>Pilot Projects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Stefano, N</creatorcontrib><creatorcontrib>Filippi, M</creatorcontrib><creatorcontrib>Confavreux, C</creatorcontrib><creatorcontrib>Vermersch, P</creatorcontrib><creatorcontrib>Simu, M</creatorcontrib><creatorcontrib>Sindic, C</creatorcontrib><creatorcontrib>Hupperts, R</creatorcontrib><creatorcontrib>Bajenaru, O</creatorcontrib><creatorcontrib>Edan, G</creatorcontrib><creatorcontrib>Grimaldi, L</creatorcontrib><creatorcontrib>Marginean, I</creatorcontrib><creatorcontrib>Medaer, R</creatorcontrib><creatorcontrib>Orefice, G</creatorcontrib><creatorcontrib>Pascu, I</creatorcontrib><creatorcontrib>Pelletier, J</creatorcontrib><creatorcontrib>Sanders, E</creatorcontrib><creatorcontrib>Scarpini, E</creatorcontrib><creatorcontrib>Mancardi, GL</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Stefano, N</au><au>Filippi, M</au><au>Confavreux, C</au><au>Vermersch, P</au><au>Simu, M</au><au>Sindic, C</au><au>Hupperts, R</au><au>Bajenaru, O</au><au>Edan, G</au><au>Grimaldi, L</au><au>Marginean, I</au><au>Medaer, R</au><au>Orefice, G</au><au>Pascu, I</au><au>Pelletier, J</au><au>Sanders, E</au><au>Scarpini, E</au><au>Mancardi, GL</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing–remitting multiple sclerosis</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2009-02-01</date><risdate>2009</risdate><volume>15</volume><issue>2</issue><spage>238</spage><epage>243</epage><pages>238-243</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><coden>MUSCFZ</coden><abstract>Objective
Two pilot studies were conducted to evaluate safety, tolerability, and efficacy of two doses of Protiramer (TV-5010) in patients with relapsing–remitting multiple sclerosis.
Background
Both glatiramer acetate and TV-5010 are synthetic copolymers comprised the same four amino acids in a defined molar ratio. TV-5010 has higher average molecular weight than Glatiramer acetate and might be hypothesized that glatiramoids with higher molecular weight might be more immunoreactive than lower molecular weight peptides, thus increasing therapeutic potential and allowing for less frequent dosing.
Methods
In the two separate studies, after a 10 week pretreatment period, TV-5010 was given subcutaneously once weekly at 15 mg and 30 mg for 36 weeks. The primary end point was a reduction in the number of magnetic resonance imaging active lesions (i.e., T1-weigthed gadolinium-enhancing and new T2-weighted lesions) between the pretreatment period and the end of study.
Results
Both TV-5010 doses were generally well tolerated. The treatment with TV-5010 at a dose of 15 mg/wk did not show any significant effect. In contrast, in patients treated with at a dose of 30 mg/wk, a significant reduction in the mean number of gadolinium-enhancing (−58.8%; P = 0.0013) and new T2-W (−50%; P = 0.0002) lesions was observed. However, a large decrease in the mean number of both gadolinium-enhancing (−55%) and new T2-W (−40%) lesions during the pretreatment period made difficult the interpretation of the efficacy assessments.
Conclusions
Further studies are needed to confirm these preliminary data on safety and efficacy of TV-5010 at a weekly dose of 30 mg.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>18987103</pmid><doi>10.1177/1352458508098269</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2009-02, Vol.15 (2), p.238-243 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66874634 |
| source | MEDLINE; SAGE Complete |
| subjects | Adult Biological and medical sciences Chemistry, Pharmaceutical Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dose-Response Relationship, Drug Female Glatiramer Acetate Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - chemistry Injections, Subcutaneous Male Medical sciences Molecular Weight Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Relapsing-Remitting - drug therapy Neurology Peptides - administration & dosage Peptides - adverse effects Peptides - chemistry Pilot Projects Treatment Outcome |
| title | The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing–remitting multiple sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T16%3A47%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20results%20of%20two%20multicenter,%20open-label%20studies%20assessing%20efficacy,%20tolerability%20and%20safety%20of%20protiramer,%20a%20high%20molecular%20weight%20synthetic%20copolymeric%20mixture,%20in%20patients%20with%20relapsing%E2%80%93remitting%20multiple%20sclerosis&rft.jtitle=Multiple%20sclerosis&rft.au=De%20Stefano,%20N&rft.date=2009-02-01&rft.volume=15&rft.issue=2&rft.spage=238&rft.epage=243&rft.pages=238-243&rft.issn=1352-4585&rft.eissn=1477-0970&rft.coden=MUSCFZ&rft_id=info:doi/10.1177/1352458508098269&rft_dat=%3Cproquest_cross%3E20449440%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218805582&rft_id=info:pmid/18987103&rft_sage_id=10.1177_1352458508098269&rfr_iscdi=true |